Introduction
The tumor microenvironment comprises various tumor cells, stromal cells, extracellular matrix and cytokines, playing an important role in tumor progression and metastasis. 1 Macrophages are the dominant migratory leukocyte population found in the tumor microenvironment. Tumor-associated macrophages (TAMs) are correlated with poor prognosis in several types of cancers including non-small-cell lung cancer (NSCLC). 2 Macrophages are differentiated from circulating bone marrow-derived
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shen et al monocytes with widely different properties depending on the external criteria. Macrophages are also highly plastic and can rapidly alter their phenotype as local signals change. The macrophages at the two extremes of possible differentiation states are the classically activated type 1 (M1) and the alternatively activated type 2 (M2). 3 M1 macrophages are polarized by lipopolysaccharide (LPS), certain Toll-like receptor (TLR) agonism, tumor necrosis factor α (TNFα), interferon-γ and mediate the innate immunity.
3,4 M1 macrophages are well adapted to express high levels of inducible nitric oxide synthase (iNOS), reactive oxygen species (ROS), TNFα, interleukin (IL)-1β, IL-6, IL-12, IL-18, IL-23, CXC ligand 10, human leukocyte antigen-DR and nitrogen intermediates. The macrophages that are exposed to Th2 cells and tumor-derived cytokines such as IL-4, IL-10, IL-13, transforming growth factor beta (TGF-β) or prostaglandin E2 (PGE2) promote M2 polarization. 5 M2 macrophages secrete vascular endothelial growth factor (VEGF), Arginase I, Ym1 (chitinase 3-like 3, also known as Ym1), Fizz1 (resistin-like beta, also known as Fizz1) and cytokines such as IL-1ra, decoy IL-1RII, IL-10, CCL17, CCL18, CCL22, polyamine, scavenger R and mannose R. M2 macrophages are associated with immunoregulation, tissue remodeling, tumor growth promotion and metastasis. 6 Common cell surface targets identified to separate M2 macrophage subsets include CD204, CD163, CD206 and CD301. 7 Meanwhile, no unique cell surface marker has yet been identified for M1 macrophages.
It has been broadly characterized that TAMs are M2-like phenotypes. 8 Over the years, significant efforts have been focused on exploiting the properties of TAMs within the tumor microenvironment. 9 NSCLC patients with high TAM density are correlated with poor survival, suggesting that TAMs are significant factors of NSCLC prognosis. 10 The cytokines expressed by TAMs can influence the tumor microenvironment and develop neoplasias and promote tumor cell migration and invasion.
IL-17 is a pleiotropic cytokine that plays a vital role in many chronic inflammatory diseases, autoimmune diseases, tumors and in host defense against bacterial and fungal infections. 11 Although it was originally considered that IL-17 was produced by T-helper cell subset, TH17 cells, recent studies showed that a wide range of innate immune cells, including γδT cells, lymphoid tissue inducer (LTi) cells, invariant natural killer T (iNKT) cells, natural killer (NK) cells and neutrophils, are also considerable sources of its early production. 12 IL-17 can promote recruitment of macrophages and induce their cytokine/chemokine production, mediating a link between acquired and innate immunity, 13 specifically T-cell and macrophage functions.
14 It has been reported that IL-17-mediated inflammation related to M1/M2 macrophage alterations induced by zoledronate may be beneficial for cancer therapy and that blocking IL-17 activity significantly decreased the M1/M2 ratio. 15 However, very little is known about the mechanism through which IL-17 mediates the polarization of macrophages. Recent studies showed that IL-17 stimulated the phosphorylation of nuclear factor kappa B inhibitor alpha (IkBα), suggesting the activation of the nuclear factor kappa B (NF-κB) signaling pathway. 16, 17 Thus, in this study, we aimed to elucidate the exact role and associated molecular mechanism of IL-17 in macrophage polarization.
In this study, we verified that IL-17 stimulated macrophages to M2-like phenotype via the NF-κB signaling pathway and that the high density of M2 macrophages was correlated with poor survival in NSCLC patients.
Patients and methods Patients
A total of 85 patients who underwent surgery with pathologically confirmed NSCLC at the Department of Pathology, Harbin Medical University Cancer Hospital, between 2006 and 2010 were enrolled in this study. No patients received any anti-tumor therapy prior to sample collection. The tumor stage was determined according to the 2010 American Joint Committee on Cancer and International Union Against Cancer tumor-node-metastasis (TNM) classification system. Tumor differentiation was graded according to the Edmondson and Steiner grading system. All experiments were performed in accordance with the relevant guidelines and regulations of Harbin Medical University. This study was approved by the ethics committee of Harbin Medical University, and written informed consent was obtained from each patient.
Cell culture and treatment
A human leukemic cell line, THP-1 cell (American Type Culture Collection, Manassas, VA, USA), was cultured in RPMI 1640 medium containing 10% fetal bovine serum, 20 µg/mL penicillin and 20 µg/mL streptomycin at 37°C in a humidified atmosphere with 5% CO 2 . The cells were differentiated into macrophages by adding 50 ng/mL of phorbol-12-myristate-13-acetate (PMA; EMD Biosciences, La Jolla, CA, USA) for 48 hours in 35 mm Petri dishes. After differentiation, THP-1 cells were, respectively, treated with 10, 20, 50 and 100 ng/ mL of recombinant human IL-17 (R&D Systems, Inc., Minneapolis, MN, USA) for 48 hours. Then, the THP-1 cells were 
Transient transfection with siRna
siRNA-p65 and negative control RNA molecules with mismatched sequences were synthesized by Oligofectamine (Thermo Fisher Scientific, Waltham, MA, USA) using the following sense and anti-sense strands: siRNA-p65-1 sense, 5′-CAAGGUGCAGAAAGA-3′ and antisense, 5′-UCUUUCUGCACCUUGUCGC-3′; siRNA-p65-2 sense, 5′-GUUUCAGCAGCUCCUGAACTT-3′ and antisense, 5′-GUUCAGGAGCUGCUGAAACTC-3′ and scramble siRNA sense, 5′-TTCAAGUCCUCGACGACUUUG-3′ and antisense 5′-CTCAAAGUCGUCGAGUUG-3′, and transfection into mouse peritoneal macrophages cells was performed using Lipofectamine™ 2000 (Thermo Fisher Scientific) according to the manufacturer's instructions.
Real-time qRT-PCR analysis
Total RNA was extracted using the Trizol reagent (Thermo Fisher Scientific) according to the manufacturer's protocol. Complementary DNA was synthesized from 500 ng of total RNA using the PrimeScript™ RT reagent kit with DNA Eraser (Takara Bio, Inc, Dalian, China). Semiquantitative real-time PCR was performed using the SYBR Green Master Mix (Hoffman-La Roche Ltd., Basel, Switzerland) on an ABI7500 Sequence Detection System (Thermo Fisher Scientific). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the internal control to correct for variations in the cDNA content among the samples. The primers were synthesized by Oligofectamine (Takara Bio, Inc) ( Table 1) . No amplification of nonspecific products was observed in any of the reactions, as determined from an analysis of the dissociation curves. inOs activity assay Cellular iNOS activity was measured by the conversion of l-arginine to NO by the use of a nitric oxide synthase assay kit (Beyotime Institute of Biotechnology).
Western blot analysis
Immunofluorescence staining and ELISA
For immunofluorescence staining, cells were fixed with 4% paraformaldehyde for 15 minutes at room temperature and permeabilized by treating with 100% methanol for 10 minutes at 20°C. Then, the slides were washed with PBS, blocked with normal goat IgG for 1 hour at room temperature and incubated overnight at 4°C with rabbit anti-NF-κB p65 antibodies (1:200; Beyotime Institute of Biotechnology) or rabbit anti-CD163 antibodies (1:100; Boster Biological Technology, Wuhan, China). Then, the slides were rinsed twice in PBS and incubated with FITC-conjugated anti-rabbit antibody (Zhongshan Golden Bridge Biotechnology) or tetramethylrhodamine-5-isothiocyanate-conjugated anti-rabbit antibody (Zhongshan Golden Bridge Biotechnology) diluted 1:100 at 37°C for 1 hour. Slides were then mounted with Prolong Gold Antifade Reagent with 40,6-diamidino-2-phenylindole (DAPI; Thermo Fisher Scientific). The fluorescent images were analyzed by fluorescence microscopy. Angiogenic factor concentrations were determined using a commercial ELISA kit (Uscn Life Science, Houston, TX, USA) according to the manufacturer's instructions.
immunohistochemistry staining
Immunohistochemistry staining was performed as previously described. 18 The primary antibodies and dilutions were as follows: anti-IL-17 antibody (1:100; Santa Cruz Biotechnology Inc., Dallas, TX, USA), anti-CD163 antibody (1:100; Boster) and anti-cellular homoloe of avian musculoaponeurotic fibrosarcoma virus oncogene (c-Maf) antibody (Abcam). The negative control sections were treated with PBS instead of the primary antibodies.
Stained tissue sections were evaluated using light microscopy at 200× or 400× magnification by two pathologists. 
statistics
Statistical analysis was performed with SPSS 17.0 software (SPSS, Chicago, IL, USA). Each treatment was performed in duplicate, and the experiment was independently repeated three times. Measurement values were expressed as mean±SD. One-way analysis of variance followed by the Student-Newman-Keuls test and Spearman's r correlation were used as appropriate. The survival rates were calculated by the Kaplan-Meier method (log-rank test). Cox multivariate analysis with a stepwise method (forward, likelihood ratio) was used to determine the independent prognostic factors. A P value of <0.05 was judged to indicate significant results.
The median values of the percentage of IL-17+ cells and of CD 163+ cells were used as cutoffs to dichotomize the immunostaining.
Results
il-17 promotes M2 macrophage differentiation in a concentrationdependent manner
To characterize the effect of IL-17 on polarized THP-1-derived macrophages to M2 phenotype, the THP-1-derived macrophages were treated with IL-17 at 0, 10, 50 and 100 ng/ mL for 48 hours. The CD206 cell surface marker of M2 macrophages was significantly increased in IL-17-treated THP-1-derived macrophages in a dose-dependent manner compared to control cultures (0 ng/mL as PBS) ( Figure  1A ). Chemokines, cytokines and enzymes linked to subsetspecific functions have helped to distinguish the macrophage phenotypes. 19 The cytokines expressed by the two subsets of macrophages were measured. We found that TGF-β, VEGF and IL-10 for M2 macrophage were produced in the IL-17-cultured medium significantly more than in control, while there was no significant difference in IL-6 for M1 macrophage ( Figure 1B ). We observed a more significant increase in mRNA levels ( Figure 1C ). The level of iNOS can be combined with the cytokines for more accurate identification of M1 macrophage. 19 After being treated with IL-17, the level of iNOS revealed no statistical difference ( Figure 1D These findings demonstrated that IL-17 plays a potential role in promoting THP-1-derived macrophages to a M2-like phenotype in a dose-dependent manner.
ThP-1-derived macrophages polarized to M2 phenotype require sustained il-17 treatment
To further dissect the functional roles of IL-17 in promoting THP-1-derived macrophages to a M2-like phenotype, we cultured the THP-1-derived macrophages in culture medium with 100 ng/mL of IL-17 for 48 hours and then cultured without IL-17 for 24 hours (48h+24h) or 48 hours (48h+48h). The CD206 was detected by flow cytometry analysis, which was significantly induced after IL-17 treatment, but this effect was eliminated by removing IL-17 ( Figure 1E ). The cytokines TGF-β, VEGF and IL-10 for M2 macrophage were increased with increase in time, but after the absence of IL-17 the expression of the cytokines was decreased ( Figure  1F and G). We demonstrated that the activation of M2-like phenotype was time dependent, increasing significantly after 24 hours of IL-17 stimulation and reaching maximal level at 48 hours. These results indicate that IL-17 is necessary for THP-1-derived macrophages to induce macrophage activation to a M2-like phenotype.
il-17 induces ThP-1-derived macrophages to a M2-like phenotype via nF-κB
Some studies have previously shown that IL-17 activates NF-κB. 20, 21 Thus, we thought to determine whether the M2 polarization observed in THP-1-derived macrophages under IL-17 conditions was attributable to increased NF-κB activity. THP-1-derived macrophages were incubated with IL-17 for 48 hours; we observed increased CD163 and CD206 levels, as determined by immunofluorescence staining and flow cytometry analysis (Figures 2A and 3 ). Immunoblotting with a specific antibody against p-IkBα was performed to detect the phosphorylation of IkBα and activation of NF-κB after IL-17 treatment. IL-17 stimulated increased phosphorylation of IkBα ( Figure 2B ), suggesting that the NF-κB pathway was activated in the IL-17-treated cells.
We investigated the potential for inhibition of NF-κB to attenuate the M2-like phenotype characteristics of IL-17-treated THP-1-derived macrophages. We used a commercially available IKK inhibitor, BAY11-7082, to pharmacologically block NF-κB activity in these cells. The BAY11-7082 inhibitor dramatically inhibited IL-17-induced expression of CD163 and CD206 and phosphorylation of IkBα (Figures 2A and 3) . IL-17 induced p65 nuclear translocation, which was inhibited by BAY11-7082 ( Figure 2C and D). We found that IL-17-induced expression of TGF-β, VEGF and IL-10 was inhibited by BAY11-7082 ( Figure 2E ), but there was no statistical difference in iNOS ( Figure 2G ). The mRNA levels of Arginase I and Fizz1 were examined in THP-1-derived macrophages. Compared with control cells, mRNA levels of Arginase I and Fizz1 were significantly increased in IL-17-treated cells. BAY11-7082 abrogated IL-17-induced increase in Arginase I and Fizz1 mRNA levels ( Figure 2F ).
il-17 induces CD203 and CD163 expression in mouse peritoneal macrophages via p65
The mouse peritoneal macrophages were cultured with 100 ng/mL of IL-17 for 48 hours and exposed to p65 siRNA (siRNA-p65-1/2) or empty vector. The isolated mouse peritoneal cells were authenticated by F4/80 and CD11b antibodies. There were 82.2% of macrophages in the isolated mouse peritoneal cells ( Figure 4A ). The level of protein and mRNA of p65 was decreased by siRNA-p65-1 and siRNA-p65-2 ( Figure 4B and C) . The levels of CD206 and CD163 were increased by IL-17, but the increase was inhibited in siRNAp65-2 cells (Figure 4D-F) . Compared with control cells, the mRNA levels of Arginase I, Fizz1 and Ym1 were significantly increased in IL-17-treated cells, but siRNA-p65-2 abrogated IL-17-induced increase in the mRNA levels of Arginase I, Fizz1 and Ym1 ( Figure 4G ).
CD163 and c-Maf expression positively correlates with il-17+ cell and predicts poor survival of nsClC patients
To determine whether our findings are clinically relevant, we examined 85 NSCLC cases from the Harbin Medical University Cancer Hospital for the expression of CD163, c-Maf and IL-17. The immunostained tissue sections revealed more IL-17+ cells in cancers with high CD163 and c-Maf expression than in cancers with low IL-17 expression (Figure 5A) . We found that the percentage of IL-17+ cells was positively correlated with the percentage of CD163+ c-Maf+ cells ( Figure 5B Figure 5C ). Similarly, there was an inverse correlation between intratumoral CD163+ cell or c-Maf+ cell density and patient survival ( Figure 5D and E) .
Univariate analysis revealed that intratumoral IL-17, CD163 and c-Maf expression were significantly associated with survival (Table 2) . Patients were classified into the following four groups: group I, IL-17+ CD163+ c-Maf+; group II, IL-17-CD163-c-Maf-; group III, IL-17+ CD163-c-Maf-and group IV, IL-17+ CD163+ c-Maf-and IL-17+CD163-c-Maf+. Significant differences in survival were detected among group I and group II, but there was no statistical difference between group III and group IV ( Figure 5F and G). Subsequently, in a multivariate COX 
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shen et al regression analysis where the presence of IL-17+ cells, CD163 expression, c-Maf expression and the combination of these markers were simultaneously adopted as covariates (Table 2) , only the combination remained statistically significant, which was the comparison between groups I and II. These results collectively suggest that the combination of intratumoral IL-17+ cells, CD163 and c-Maf expression serve as a better prognosis marker in NSCLC patients than either marker alone.
Discussion
In this study, we show that IL-17 plays a potential role in promoting macrophages to a M2-like phenotype in a dosedependent manner, which needs IL-17-persistent treatment. TAMs have been shown to promote tumor progression, and increased TAM infiltration often correlates with poor prognosis. 22 In previous study, TAMs are characterized as mainly M2-like macrophages, which express a typical M2 marker profile including mannose receptor, a low MHC class II complex, stabilin-1 and Arginase I. 3 Cumulative evidence has highlighted a link between IL-17 and M2 polarization in several types of cancers. 23 We found that IL-17 treatment had a significant impact on M2 polarization, as evidenced by increased expression of M2 cell surface markers CD206 and CD163 in THP-1-derived macrophages and the mouse peritoneal macrophages. TAMs are often considered protumor due to secretion of growth-and angiogenesis-promoting factors. 24 These include the secretion of anti-inflammatory cytokines such as IL-10, CCL22 and TGF-β, which can downmodulate macrophage ROS intermediates. Altogether, these factors suggest that enrichment of TAMs within the tumor microenvironment supports tumor growth and metastasis. 25 Consistent with our previous study, we found that IL-17 induced the higher levels of VEGF, which involved in angiogenesis promoting tumor metastasis. 18 Meanwhile, IL-10 and TGF-β were increased after IL-17 treatment, which were anti-inflammatory cytokines in the tumor microenvironment supporting tumor growth. 26 Unlike findings from a previous study, our data suggest that the levels of IL-6 did not show significant change, this may due to the different types of cells. 27 Interestingly, after removing the stimulation of IL-17, the level of CD206 was gradually decreased. Our findings support the notion that IL-17 can promote M2-like phenotype in macrophages.
A number of downstream effectors can be activated by IL-17, the best studied member of this cytokine family, including the transcription factors NF-κB, C/EBP and AP-1, as well as MAP kinases. 28 NF-κB is an important transcription factor in regulating gene transcription. The activation of NF-κB was demonstrated by not only IkBα degradation and p65 translocation into the nucleus but also the binding of p65 to the targeted gene promoter. 29 A previous study showed that IL-17-induced epithelial-mesenchymal transition promoted lung cancer cell migration and invasion via the NF-κB signal pathway. 16 Combining all these reports, we sought to determine whether the NF-κB signaling pathway participates in the IL-17-induced M2-like phenotype. Our study showed that p-IkBα level and p65 nuclear translocation were increased in THP-1-derived macrophages treated with IL-17. When THP-1-derived macrophages were treated with the NF-κB inhibitor BAY11-7082, the increased p-IkBα level and p65 nuclear translocation induced by IL-17 were attenuated. In addition, the increased CD206 level was inhibited by siRNA-p65 in the mouse peritoneal macrophages. Thus, our results indicated that IL-17 activates the NF-κB 
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IL-17 induces macrophages to M2-like phenotype via NF-κB signaling pathway in macrophages. Arginase I, Ym1 and Fizz1 were secreted by M2 macrophages. The mRNA levels of Arginase I and Fizz1 in IL-17-treated THP-1-derived macrophages and Arginase I, Ym1 and Fizz1 in IL-17-treated mouse peritoneal macrophages were increased, which was abrogated by BAY 11-7082 and siRNA-p65-2, respectively. Based on these data, IL-17 induces macrophages to M2-like phenotype via NF-κB.
Tumor necrosis factor receptor-associated factor 3 (TRAF3) and interacting protein 2 (also known as Act1; CIKS) have been shown to be recruited to IL-17 receptor (IL-17R) through its SEF/IL-17R/CIKS/ACT1 homology (SEFIR) domain in an IL-17 stimulation-dependent manner.
30
Act1 was discovered to be essential for IL-17-induced activation of NF-κB. The inducible kinase IKKi (also named IKKe) was found to mediate the Act1-dependent and TRAF6-independent pathway. IKKi was shown to associate with Act1 in response to IL-17 treatment in mouse fibroblasts. 31 Thus, Act1 serves as a receptor proximal anchor platform for the initiation of NF-κB pathways activated by IL-17. In TNFα-mediated signaling, K63-linked TRAF6 polyubiquitination associates with the TAK1 complex and activates the kinase TAK1 and subsequently leads to the IKK complex and classic NF-κB activation. 32 The exact molecular mechanisms of IL-17 phosphorylating IkBα and activating NF-κB remain to be solved.
Recently, Xu et al have shown that lung cancer patients with pleural fluid IL-17 levels below 15 pg/mL had longer OS than those patients with higher levels (10.8 vs 4.7 months; P<0.05). 33 Consistent with these previous results, we found that IL-17 is associated with poor prognosis and that intratumoral IL-17-producing cells are positively correlated with CD163 and c-Maf in human NSCLC tissues. Barros et al reported that CD163 combination with c-Maf served to identify M2 macrophages better. 34 Although consistent with several recent publications regarding the role of IL-17 in promoting tumor progress, these findings contradict other reports, suggesting that IL-17 can provide an antitumor effect against certain tumors. Furthermore, the combination of intratumoral IL-17+ cells, CD163 and c-Maf expression served as a better predictor of poor survival than any alone in NSCLC patients.
